Oxymetazoline in the treatment of allergic and non-infectious conjunctivitis.
In a double-blind study of 141 patients, 0.025% oxymetazoline ophthalmic solution was compared with its vehicle in the treatment of allergic and non-infectious conjunctivitis. There was a marked difference in response at the first evaluation. By the tenth day (second evaluation) the total improvement in hyperaemia was 95% for oxymetazoline compared to 54% for the placebo. Oxymetazoline's decongestant effect in the eye matches its effect as a nasal vasoconstrictor.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D003231:Conjunctivitis / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D010109:Oxymetazoline / Q000008:administration & dosage*; D010919:Placebos; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy*; D014662:Vasoconstrictor Agents / Q000008:administration & dosage
D007093:Imidazoles; D009883:Ophthalmic Solutions; D010919:Placebos; D014662:Vasoconstrictor Agents; D010109:Oxymetazoline